Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study.

MLA

Tacchetti, Paola, et al. “Bortezomib, Thalidomide, and Dexamethasone Followed by Double Autologous Haematopoietic Stem-Cell Transplantation for Newly Diagnosed Multiple Myeloma (GIMEMA-MMY-3006): Long-Term Follow-up Analysis of a Randomised Phase 3, Open-Label Study.” The Lancet. Haematology, vol. 7, no. 12, Dec. 2020, pp. e861–73. EBSCOhost, https://doi.org/10.1016/S2352-3026(20)30323-9.

APA

Tacchetti, P., Pantani, L., Patriarca, F., Petrucci, M. T., Zamagni, E., Dozza, L., Galli, M., Di Raimondo, F., Crippa, C., Boccadoro, M., Barbato, S., Tosi, P., Narni, F., Montefusco, V., Testoni, N., Spadano, A., Terragna, C., Pescosta, N., Marzocchi, G., … Cavo, M. (2020). Bortezomib, thalidomide, and dexamethasone followed by double autologous haematopoietic stem-cell transplantation for newly diagnosed multiple myeloma (GIMEMA-MMY-3006): long-term follow-up analysis of a randomised phase 3, open-label study. The Lancet. Haematology, 7(12), e861–e873. https://doi.org/10.1016/S2352-3026(20)30323-9

Chicago

Tacchetti, Paola, Lucia Pantani, Francesca Patriarca, Maria Teresa Petrucci, Elena Zamagni, Luca Dozza, Monica Galli, et al. 2020. “Bortezomib, Thalidomide, and Dexamethasone Followed by Double Autologous Haematopoietic Stem-Cell Transplantation for Newly Diagnosed Multiple Myeloma (GIMEMA-MMY-3006): Long-Term Follow-up Analysis of a Randomised Phase 3, Open-Label Study.” The Lancet. Haematology 7 (12): e861–73. doi:10.1016/S2352-3026(20)30323-9.